A Phase 1/2a Open-Label, Dose-Escalation/Dose-Expansion Safety, Tolerability and Pharmacokinetic Study of IMX-110 in Patients With Advanced Solid Tumors

Trial Profile

A Phase 1/2a Open-Label, Dose-Escalation/Dose-Expansion Safety, Tolerability and Pharmacokinetic Study of IMX-110 in Patients With Advanced Solid Tumors

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 08 Mar 2018

At a glance

  • Drugs IMX-110 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors Immix Biopharma Australia
  • Most Recent Events

    • 27 Feb 2018 Status changed from not yet recruiting to recruiting.
    • 05 Jan 2018 According to an Immix Biopharma media release, Professor de Souza from Western Sydney University is the principal investigator for this study.
    • 05 Jan 2018 According to an Immix Biopharma media release, Human Research Ethics Committee (IRB) approval has been recieved for this study.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top